Immune response analysis to immunotherapy in cervical cancer patients' tissues
2019
Cancer Center Amsterdam, Amsterdam, Netherlands
Cervical cancer (CxCa) is still the second most diagnosed cancer among women worldwide, its development is associated with the suppression of T-cell responses against human papillomavirus (HPV). Although many clinical trials have shown that releasing immunosuppressive brakes on effector T cells, like programmed cell death−ligand-1 (PD-(L)1), leads to responses in various cancer types; no reliable biomarkers predictive of clinical response on PD-1 blockade have been identified yet. In the present study, the researchers aimed at identifying immunotherapeutic targets on T cells performing flow cytometry profiling on T cells from patients' tumors. The data revealed that local PD-(L)1 blockade could interrupt loco-regional immune suppression in CxCa. Furthermore, the data identify a specific subset of T cells as therapeutic targets, which may also serve as a predictive biomarker for PD-(L)1 checkpoint blockade.
Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels
T. D. de Gruijl
Added on: 09-17-2021
[1] https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0526-z[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
